Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma-Reference-Cited by-同舟云学术

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma

Published:2017-05-16 Issue:17 Volume:23 Page:5024-5033
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Vilain Ricardo E.,Menzies Alexander M.,Wilmott James S.,Kakavand Hojabr,Madore Jason,Guminski Alexander,Liniker Elizabeth,Kong Benjamin Y.,Cooper Adam J.,Howle Julie R.,Saw Robyn P.M.,Jakrot Valerie,Lo Serigne,Thompson John F.,Carlino Matteo S.,Kefford Richard F.,Long Georgina V.,Scolyer Richard A.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 203 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of immune checkpoint inhibitors combined with bevacizumab in MSS/pMMR advanced colorectal cancer after first-line treatment failure;Frontiers in Oncology;2024-08-12

2. Pan‐cancer evaluation of tumor‐infiltrating lymphocytes and programmed cell death protein ligand‐1 in metastatic biopsies and matched primary tumors;The Journal of Pathology;2024-07-29

3. Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab;npj Precision Oncology;2024-07-19

4. Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers;Journal for ImmunoTherapy of Cancer;2024-07

5. Seasonal influences on the efficacy of anti–programmed cell death (ligand) 1 inhibitors in lung cancer;Cancer;2024-06-28